Trevi Therapeutics (NASDAQ:TRVI) Price Target Raised to $12.50

Trevi Therapeutics (NASDAQ:TRVI) had its price target raised by HC Wainwright from $7.50 to $12.50 in a research note released on Monday,Benzinga reports. They currently have a buy rating on the stock.

TRVI has been the topic of a number of other reports. D. Boral Capital reissued a “buy” rating and set a $21.00 target price on shares of Trevi Therapeutics in a report on Friday, March 7th. Raymond James raised shares of Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their target price for the stock from $9.00 to $29.00 in a report on Monday. Finally, Needham & Company LLC boosted their target price on shares of Trevi Therapeutics from $8.00 to $25.00 and gave the stock a “buy” rating in a report on Monday. Seven investment analysts have rated the stock with a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $15.94.

Trevi Therapeutics Price Performance

TRVI opened at $6.30 on Monday. Trevi Therapeutics has a fifty-two week low of $2.30 and a fifty-two week high of $7.39. The firm has a market capitalization of $484.26 million, a price-to-earnings ratio of -14.32 and a beta of 0.90. The company’s 50 day moving average price is $4.26 and its two-hundred day moving average price is $3.58.

Insider Activity at Trevi Therapeutics

In related news, insider Farrell Simon sold 81,313 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $6.75, for a total transaction of $548,862.75. Following the transaction, the insider now owns 76,900 shares in the company, valued at $519,075. The trade was a 51.39 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 24.37% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Summit Investment Advisors Inc. lifted its position in shares of Trevi Therapeutics by 84.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company’s stock valued at $26,000 after acquiring an additional 2,894 shares during the period. Bank of New York Mellon Corp lifted its position in shares of Trevi Therapeutics by 2.1% during the 4th quarter. Bank of New York Mellon Corp now owns 140,219 shares of the company’s stock valued at $578,000 after acquiring an additional 2,935 shares during the period. SG Americas Securities LLC raised its holdings in Trevi Therapeutics by 14.5% during the fourth quarter. SG Americas Securities LLC now owns 26,792 shares of the company’s stock worth $110,000 after buying an additional 3,387 shares during the last quarter. Invesco Ltd. raised its holdings in Trevi Therapeutics by 21.2% during the fourth quarter. Invesco Ltd. now owns 23,621 shares of the company’s stock worth $97,000 after buying an additional 4,133 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in Trevi Therapeutics by 32.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 25,166 shares of the company’s stock worth $104,000 after buying an additional 6,119 shares during the last quarter. Institutional investors and hedge funds own 95.76% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.